
|Articles|August 11, 2015
Shire Re-Opens Baxalta Takeover Talks
August 11, 2015.
Advertisement
Shire is set to re-open its formal takeover talks Baxalta, reports
Going public on its offer for Baxalta last week, Shire claimed the deal would create the world’s leading rare diseases specialist and generate $20bn in product sales by 2020.
Baxalta spurned initial advances, but The Independent reports that "Mr Ornskov and his chairman, Susan Kilsby, have spent the past few days crossing the Atlantic and meeting its rival’s shareholders, who are warming to the idea of a multibillion-dollar tie-up."
In order to re-open talks Shire needs to increase its offer beyond $30bn (£20bn).
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond Amyloid, Part One (of two): Tau and Microglia Redefine the Alzheimer’s Pipeline
2
What the Peptide Advisory Vote Actually Means: Q&A with James LaValle
3
Hanmi Pharm Enters $2.3 Billion Licensing Agreement with Genentech for HM17321
4
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
5




